Bradley R. Corr

1.3k total citations
64 papers, 699 citations indexed

About

Bradley R. Corr is a scholar working on Oncology, Reproductive Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Bradley R. Corr has authored 64 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 27 papers in Reproductive Medicine and 23 papers in Obstetrics and Gynecology. Recurrent topics in Bradley R. Corr's work include Ovarian cancer diagnosis and treatment (27 papers), Endometrial and Cervical Cancer Treatments (23 papers) and Cancer Genomics and Diagnostics (7 papers). Bradley R. Corr is often cited by papers focused on Ovarian cancer diagnosis and treatment (27 papers), Endometrial and Cervical Cancer Treatments (23 papers) and Cancer Genomics and Diagnostics (7 papers). Bradley R. Corr collaborates with scholars based in United States, Spain and Italy. Bradley R. Corr's co-authors include Saketh R. Guntupalli, Jeanelle Sheeder, Kian Behbakht, Christina Chu, Gina Mantia-Smaldone, Elizabeth R. Woodruff, Benjamin G. Bitler, Carolyn Lefkowits, Casey Cosgrove and Alexandra McMellen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Bradley R. Corr

56 papers receiving 690 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bradley R. Corr United States	14	246	210	202	154	97	64	699
Laura Attademo Italy	13	225 0.9×	54 0.3×	103 0.5×	172 1.1×	111 1.1×	21	560
Katrin Hefler‐Frischmuth Austria	11	204 0.8×	77 0.4×	153 0.8×	31 0.2×	37 0.4×	17	479
Masako Shida Japan	13	58 0.2×	192 0.9×	189 0.9×	67 0.4×	11 0.1×	36	458
Roberta Tana Italy	17	183 0.7×	399 1.9×	330 1.6×	166 1.1×	2 0.0×	22	803
Edem Agamah United States	12	176 0.7×	65 0.3×	49 0.2×	151 1.0×	4 0.0×	16	560
Robin Laskey United States	7	156 0.6×	301 1.4×	223 1.1×	107 0.7×	2 0.0×	9	679
Sally Baron‐Hay Australia	14	388 1.6×	148 0.7×	220 1.1×	237 1.5×		48	775
Kiyoshi Kubochi Japan	10	212 0.9×	21 0.1×	22 0.1×	45 0.3×	16 0.2×	30	433
Vincent Dochez France	10	116 0.5×	190 0.9×	235 1.2×	154 1.0×	1 0.0×	47	692

Countries citing papers authored by Bradley R. Corr

Since Specialization

Citations

This map shows the geographic impact of Bradley R. Corr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bradley R. Corr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bradley R. Corr more than expected).

Fields of papers citing papers by Bradley R. Corr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bradley R. Corr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bradley R. Corr. The network helps show where Bradley R. Corr may publish in the future.

Co-authorship network of co-authors of Bradley R. Corr

This figure shows the co-authorship network connecting the top 25 collaborators of Bradley R. Corr. A scholar is included among the top collaborators of Bradley R. Corr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bradley R. Corr. Bradley R. Corr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Joyce F., Nicoletta Colombo, Amit M. Oza, et al.. (2025). ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma. Journal of Clinical Oncology. 43(26). 2897–2907. 5 indexed citations

Corr, Bradley R., Britt Erickson, Emma L. Barber, Christine M. Fisher, & Brian M. Slomovitz. (2025). Advances in the management of endometrial cancer. BMJ. 388. e080978–e080978. 6 indexed citations

Corr, Bradley R., Ashley Haggerty, Sarah E. Taylor, et al.. (2025). A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. Gynecologic Oncology. 200. 58–67.

Lee, Sarah S., Steven G. Friedman, Lindsay Borden, et al.. (2025). Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2). Gynecologic Oncology. 199. 152–158.

Davis, S. Lindsey, Wells A. Messersmith, W. Thomas Purcell, et al.. (2024). A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors. Cancers. 16(8). 1456–1456.

Bickerdike, Mike, Kimberly R. Jordan, Bradley R. Corr, et al.. (2024). Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression. Cancer Research Communications. 4(3). 822–833. 9 indexed citations

Corr, Bradley R., Ashley Haggerty, Stefan Gysler, et al.. (2024). A phase II, randomized, double-blind study of the use of rucaparib versus placebo maintenance therapy in metastatic and recurrent endometrial cancer. Gynecologic Oncology. 190. S63–S63.

Corr, Bradley R., et al.. (2024). 718MO Mirvetuximab soravtansine (MIRV) in recurrent platinum-sensitive ovarian cancer (PSOC) with high folate receptor-alpha (FRα) expression: Results from the PICCOLO trial. Annals of Oncology. 35. S549–S550. 5 indexed citations

Santin, Alessandro D., Bradley R. Corr, Alexander I. Spira, et al.. (2024). Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. Journal of Clinical Oncology. 42(29). 3421–3429. 20 indexed citations

10.

González-Martı́n, Antonio, Hyun Cheol Chung, Esma Saâda-Bouzid, et al.. (2024). Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. Gynecologic Oncology. 186. 182–190. 8 indexed citations

11.

Smith, Lynelle P., Bradley R. Corr, Christine M. Fisher, et al.. (2023). Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry—Real-World Implementation and Results at a Tertiary Care Center. International Journal of Gynecological Pathology. 43(4). 335–348. 1 indexed citations

12.

Liu, Joyce F., Nicoletta Colombo, Amit M. Oza, et al.. (2023). ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma (039). Gynecologic Oncology. 176. S33–S35. 4 indexed citations

13.

Sottnik, Joseph L., Sydney K. Robinson, Steffi Oesterreich, et al.. (2023). WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers. Cancer Research Communications. 4(1). 134–151. 4 indexed citations

14.

Fu, Siqing, Bradley R. Corr, Kerry Culm-Merdek, et al.. (2022). Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Journal of Clinical Oncology. 40(23). 2568–2577. 36 indexed citations

15.

McMellen, Alexandra, et al.. (2020). Wnt Signaling in Gynecologic Malignancies. International Journal of Molecular Sciences. 21(12). 4272–4272. 49 indexed citations

16.

Diamond, John B., Gary Gordon, Bradley R. Corr, et al.. (2020). Initial results from a phase 1 trial of OKI-179, an oral Class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors. European Journal of Cancer. 138. S12–S12. 1 indexed citations

17.

Brubaker, Lindsay W., et al.. (2019). Clinical presentation of brain metastases from endometrial carcinoma: A case series. Gynecologic Oncology Reports. 28. 79–83. 10 indexed citations

18.

Amini, Arya, Tyler P. Robin, Chad G. Rusthoven, et al.. (2018). Rising Rates of Upfront Surgery in Early Locally Advanced Cervical Cancer. International Journal of Gynecological Cancer. 28(8). 1560–1568. 10 indexed citations

19.

Davis, S. Lindsey, Elaine T. Lam, Bradley R. Corr, et al.. (2018). Abstract A083: A phase Ib study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors. Molecular Cancer Therapeutics. 17(1_Supplement). A083–A083. 1 indexed citations

20.

Doo, David W., Saketh R. Guntupalli, Bradley R. Corr, et al.. (2015). Comparative Surgical Outcomes for Endometrial Cancer Patients 65 Years Old or Older Staged With Robotics or Laparotomy. Annals of Surgical Oncology. 22(11). 3687–3694. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact